A Randomized, Double-blind Placebo-controlled and Open-label Active-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Subjects
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Efinopegdutide (Primary) ; Liraglutide
- Indications Obesity
- Focus Adverse reactions; Therapeutic Use
- Sponsors Janssen Research & Development
- 04 Apr 2019 Status changed from active, no longer recruiting to completed.
- 26 Feb 2019 Planned End Date changed from 8 Mar 2019 to 12 Mar 2019.
- 26 Feb 2019 Planned primary completion date changed from 21 Jan 2019 to 12 Mar 2019.